Fig. 1: Free HARS is present in the circulation and low or absent in anti-Jo-1-positive disease.
From: Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses
a Free-serum HARS levels measured in normal human volunteers (n = 115), anti-Jo-1-positive myositis patients (n = 61), and patients with anti-Jo-1-negative myositis (n = 286). Each dot represents an individual patient. Bars represent median values. Significantly lower levels of free HARS (****p < 0.0001) were observed in the anti-Jo-1-positive myositis patients compared to normal individuals and anti-Jo-1-negative myositis (n = 286) patients. b Serum HARS level in patients with ILD (n = 94) and without ILD (n = 243) were segmented by Jo-1 status (ILD+ Jo-1− n = 50, ILD− Jo-1− n = 236, ILD+, Jo-1+ n = 44, ILD− Jo-1+ n = 7). c HARS-specific antibody levels in healthy volunteers were compared to individuals with Jo-1-positive and Jo-1-negative myositis (sample numbers as in a). d Correlation of HARS serum levels with anti-HARS antibodies (data from panels a and c).
